Coya Therapeutics (COYA) Accounts Payables (2021 - 2026)

Coya Therapeutics (COYA) has 6 years of Accounts Payables data on file, last reported at $948192.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 43.89% year-over-year to $948192.0; the trailing twelve-month figure through Mar 2026 stood at $948192.0 (down 43.89% YoY), and the FY2025 full-year result was $1.1 million, down 33.18% from the prior year.
• Accounts Payables retreated to $948192.0 in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.9 million in Q2 2024 to a low of $237579.0 in Q2 2023.
• A 5-year average of $1.1 million and a median of $1.1 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 692.61% in 2024 and plunged 50.54% in 2025, its largest moves.
• Tracing COYA's Accounts Payables over 5 years: stood at $1.8 million in 2022, then plunged by 36.34% to $1.2 million in 2023, then surged by 37.42% to $1.6 million in 2024, then slumped by 33.18% to $1.1 million in 2025, then slipped by 10.64% to $948192.0 in 2026.
• Business Quant data shows COYA's Accounts Payables at $948192.0 in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.